CC
DNTH icon

Casdin Capital’s Dianthus Therapeutics DNTH Stock Holding History

Casdin Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,000
Closed -$451K – 48
2022
Q3 		$451K Sell
20,000
-130,938
-87% -$3.58M 0.03% 35
2022
Q2 		$2.9M Sell
150,938
-22,404
-13% -$554K 0.25% 35
2022
Q1 		$8.04M Sell
173,342
-70,507
-29% -$3.85M 0.36% 40
2021
Q4 		$17.3M Hold
243,849
– – 0.49% 38
2021
Q3 		$28.4M Buy
243,849
+34,722
+17% +$4.05M 0.71% 36
2021
Q2 		$32.7M Hold
209,127
– – 0.83% 30
2021
Q1 		$39.6M Hold
209,127
– – 1.18% 24
2020
Q4 		$26.2M Hold
209,127
– – 0.78% 28
2020
Q3 		$22.8M Hold
209,127
– – 1.02% 23
2020
Q2 		$25.1M Buy
209,127
+23,437
+13% +$3.3M 1.49% 24
2020
Q1 		$18.7M Sell
185,690
-7,943
-4% -$1.47M 1.98% 18
2019
Q4 		$47M Buy
193,633
+3,125
+2% +$584K 4.32% 11
2019
Q3 		$31.3M Buy
190,508
+2,813
+1% +$534K 3.24% 12
2019
Q2 		$44.3M Buy
187,695
+22,488
+14% +$5.56M 4.15% 11
2019
Q1 		$43.5M Hold
165,207
– – 4.78% 8
2018
Q4 		$15.1M Buy
165,207
+24,531
+17% +$3.34M 2.58% 17
2018
Q3 		$27M Buy
140,676
+13,437
+11% +$2.83M 3.29% 13
2018
Q2 		$27.5M Buy
+127,239
New +$28.7M 3.84% 11

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital's DNTH Position: Q4 2022 in Review

Casdin Capital sold out of Dianthus Therapeutics (DNTH) in Q4 2022, closing a stake of 20,000 shares — an estimated $451K sold.

Casdin Capital first reported a position in DNTH in Q2 2018 and held it in 18 quarters. The position peaked at $47M in Q4 2019. 53 funds tracked by Wall St. Rank hold DNTH as of Q4 2022.

  • Casdin Capital reported no remaining Dianthus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Casdin Capital sold 20,000 Dianthus Therapeutics shares in Q4 2022, an estimated $451K.
  • Casdin Capital first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 18 quarters.
  • Casdin Capital's Dianthus Therapeutics position peaked at $47M in Q4 2019.
  • 53 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2022.

Based on Casdin Capital's 13F filing for Q4 2022, filed 14 Feb 2023.